Doses of anti-VEGF agents are higher when administered systemically than when delivered by intravitreal injection, and anti-VEGF therapy for the treatment of cancer is thought to be linked to a reduced production of nitric oxide and prostacyclin and increased production of erythropoietin, both of which can increase the risk of arterial thromboembolic events [23]. The gene discussed is EPO; the disease is cancer.